Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs

NCT02200380 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02200380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02200380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2014
Completion date
April 13, 2016
Enrollment
36 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all), acute myelogenous leukemia (aml), chronic lymphocytic leukemia (cll), chronic myelogenous leukemia (cml), for donors, for recipients, hodgkins disease (hd), myelodysplastic syndrome (mds), non-hodgkins lymphoma (nhl), related donors giving peripheral blood stem cells (pbsc) to a sibling